1-5 of 5
Faith Galderisi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2 ) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Lorenzo Falchi, Franck Morschhauser, Kim Linton, Huiqiang Huang, Faith Galderisi, Syed Quadri, Lingmin Zeng, Daniela Hoehn, John F. Seymour
Journal: Blood
Blood (2023) 142 (Supplement 1): 3053.
https://doi.org/10.1182/blood-2023-180092
Published: 2023
Journal Articles

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Joshua Brody, Judit Mészáros Joergensen, David Belada, Regis T. Costello, Marek Trněný, Umberto Vitolo, David Lewis, Yasmin H. Karimi, Anna Maria Sureda Balari, Marc André, Björn E. Wahlin, Pieternella Lugtenburg, Faith Galderisi, Aqeel Abbas, Yaou Song, Malene Risum, Raul Cordoba
Journal: Blood
Blood (2023) 142 (Supplement 1): 3092.
https://doi.org/10.1182/blood-2023-180246
Published: 2023
Journal Articles

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Susan Prockop, Laurence Gamelin, Rajani Dinavahi, Yan Sun, Weizhi Zhao, Faith Galderisi, Aditi Mehta
Journal: Blood
Blood (2021) 138 (Supplement 1): 887.
https://doi.org/10.1182/blood-2021-147226
Published: 2021
Journal Articles

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)

Ranjana H. Advani, MD, Alison J. Moskowitz, MD, Nancy L. Bartlett, MD, Julie M. Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MSc, Beth A. Christian, MD, Stephen M. Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Carol Anne Ogden, PhD, David Taft, Daniel E. Zak, PhD, Mariana Sacchi, MD, Faith Galderisi, DO, Alex F. Herrera, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1635.
https://doi.org/10.1182/blood-2018-99-110002
Published: 2018
Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw
Journal: Blood
Blood (2018) 132 (Supplement 1): 927.
https://doi.org/10.1182/blood-2018-99-111279
Published: 2018